| Objective：To evaluate the influence of antiviral treatment on survival in patients withhepatitis B related hepatocellular carcinoma.Methods：329cases of hepatitis B related hepatocellular carcinoma patients in ourhospital from Jan2010to Dec2010were enrolled in this study. The deadline of followingup was Dec2011. The treatment include surgery resection, TACE, radiofrequency ablation,palliative care. All patients were divided into two groups: antiviral therapy group andnon-antiviral therapy group. To compare the difference of survival within12monthbetween2groups. Multivariate Cox proportional hazards model was used to analyze thefollowing factors: the age when tumor was found, tumor size, tumor number, portalmetastasis, peritoneal metastasis, pleural metastasis, Child-Pugh classification, surgeryresection, TACE，radiofrequency ablation, palliative care, antiretroviral treatment.Results：There was significant difference on overall survival curves between antiviraltherapy group and non-antiviral therapy group in329patients with hepatitis B relatedhepatocellular carcinoma（χ2=64.926, P=0.000） There were significant difference onsurvival curves between those group that antiviral treatment combine with surgeryresectionã€TACE, radiofrequency ablation, palliative care and group without antiviraltreatment （χ2=5.099，P=0.024；χ2=5.02P=0.025；χ2=22.534P=0.000；χ2=5.21P=0.022） Multivariate analysis showed that surgery resection,Child-Pugh classification,portal vein tumor thrombus, radiofrequency ablation, pleural metastasis and palliative care, antiviral treatment were related with prognosis.Conclusion：Antiviral treatment can extend the survival of patients with hepatitis Brelated hepatocellular carcinoma. Child-Pugh classification, portal vein tumor thrombus,pleural metastasis, palliative care were risk factors affecting the prognosis of thosepatients. Surgery resection TACE radiofrequency ablation, antiviral treatment wereprotective factors affecting the prognosis of those patients. |
PDF Full Text Request